logo
  

Radius Reports Positive Phase 3 Results For TYMLOS Subcutaneous Injection In Males With Osteoporosis

Radius Health Inc. (RDUS) announced positive results from the ATOM Phase 3 Study evaluating TYMLOS or abaloparatide 80mcg subcutaneous (SC) for use in males with osteoporosis. The company remains on track for an sNDA submission in the first quarter of 2022.

The study met its primary endpoint - the percentage change in lumbar spine (LS) bone mineral density (BMD) compared to placebo - demonstrating statistical significance after 12 months. Study participants receiving abaloparatide-SC experienced an average increase in LS BMD of 8.5% compared to patients receiving the placebo experiencing an average increase of 1.2%.

The study also met secondary endpoints, which measured the percentage change compared to placebo for lumbar spine BMD at 6 months, total hip BMD at 12 months, and femoral neck BMD at 12 months.

The company noted that the safety profile of abaloparatide in the ATOM study was consistent with results in previously reported trials.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
United Airlines has opened its flight training school, United Aviate Academy, to bring out new pilots with a view to mainly empower women and people of color. The institute's first class of students is 80 percent women or people of color. This outpaces the airline's earlier goal to train about 5,000 new pilots at the school by 2030 with at least half being women or people of color. French telecom major Orange SA (ORAN) announced Friday that the company's Board of Directors, which met today, has appointed Christel Heydemann as the Chief Executive Officer of Orange with effect from April 4. The Board has asked Stéphane Richard to continue as Chairman & CEO until Heydemann takes... California-based Blaine Labs Co. is recalling one lot of RevitaDerm Wound Care to the consumer level citing the potential contamination with Bacillus cereus, the U.S. Food and Drug Administration said. The product is used as a skin wound antimicrobial. It is packaged in a 1.0 ounce bottle and a 3.0 ounce tube with each labeled as "RevitaDerm Wound Care Gel" with a Drug Facts label on the back.
Follow RTT